Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.

Grinda T, Heiling HM, Tayob N, Smith KL, Davis R, Cotter C, DeMeo MK, Santa-Maria CA, Van Poznak C, Moy B, Brufsky AM, Melisko ME, O'Sullivan CC, Isaacs C, Rauf Y, Nangia JR, Burns RT, Savoie J, Wolff AC, Winer EP, Mayer EL, Tolaney SM, Rimawi MF, Ruddy KJ, Rocque G, Krop IE, Lin NU, Freedman RA

Open source

DOI: 10.1016/j.breast.2026.104881
Published: 2026 Oct
Container: Breast (Edinburgh, Scotland)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.breast.2026.104881,
  title = {Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.},
  author = {Grinda T and Heiling HM and Tayob N and Smith KL and Davis R and Cotter C and DeMeo MK and Santa-Maria CA and Van Poznak C and Moy B and Brufsky AM and Melisko ME and O'Sullivan CC and Isaacs C and Rauf Y and Nangia JR and Burns RT and Savoie J and Wolff AC and Winer EP and Mayer EL and Tolaney SM and Rimawi MF and Ruddy KJ and Rocque G and Krop IE and Lin NU and Freedman RA},
  year = {2026},
  journal = {Breast (Edinburgh, Scotland)},
  doi = {10.1016/j.breast.2026.104881},
  url = {https://doi.org/10.1016/j.breast.2026.104881}
}

RIS

TY  - JOUR
TI  - Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.
AU  - Grinda T
AU  - Heiling HM
AU  - Tayob N
AU  - Smith KL
AU  - Davis R
AU  - Cotter C
AU  - DeMeo MK
AU  - Santa-Maria CA
AU  - Van Poznak C
AU  - Moy B
AU  - Brufsky AM
AU  - Melisko ME
AU  - O'Sullivan CC
AU  - Isaacs C
AU  - Rauf Y
AU  - Nangia JR
AU  - Burns RT
AU  - Savoie J
AU  - Wolff AC
AU  - Winer EP
AU  - Mayer EL
AU  - Tolaney SM
AU  - Rimawi MF
AU  - Ruddy KJ
AU  - Rocque G
AU  - Krop IE
AU  - Lin NU
AU  - Freedman RA
PY  - 2026
JO  - Breast (Edinburgh, Scotland)
DO  - 10.1016/j.breast.2026.104881
UR  - https://doi.org/10.1016/j.breast.2026.104881
ER  -

APA

T, G., HM, H., N, T., KL, S., R, D., C, C., MK, D., CA, S., C, V. P., B, M., AM, B., ME, M., CC, O., C, I., Y, R., JR, N., RT, B., J, S., AC, W., EP, W., EL, M., SM, T., MF, R., KJ, R., G, R., IE, K., NU, L., & RA, F. (2026). Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.. Breast (Edinburgh, Scotland). https://doi.org/10.1016/j.breast.2026.104881

Source records

pubmed · retrieved 2026-09-26T07:26:46.963Z